News | March 17, 2024
Sumitomo Pharma announces availability of ORGOVYX in Canada
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The brands Aarne in Germany and Nalcrom in Canada and the Netherlands are being acquired
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
WINLEVI works differently from any other topical acne treatment
Propranolol LA is a generic equivalent of Inderal LA
The US FDA in its communication mentioned it may withhold approval of any pending applications or supplements in which this facility is listed.
The introduction of Octasa 1600 mg to the Canadian market is expected to increase the options for UC patients managed with mesalazine.
Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)